沙利度胺预防卡瑞利珠单抗所致皮肤毛细血管内皮细胞增生症。
Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
机构信息
Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
出版信息
Australas J Dermatol. 2022 May;63(2):217-221. doi: 10.1111/ajd.13812. Epub 2022 Mar 1.
Abstract
OBJECTIVES
The study evaluated the efficacy of thalidomide in prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP).
METHODS
In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed.
RESULTS
A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively. The adverse events of thalidomide were mild, and no treatment-associated interruption was observed.
CONCLUSIONS
Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.
摘要
目的
本研究评估了反应性皮肤毛细血管内皮增殖（RCCEP）中沙利度胺预防卡瑞利珠单抗的疗效。
方法
本研究纳入了接受卡瑞利珠单抗联合沙利度胺或卡瑞利珠单抗单药治疗的患者。分析了 RCCEP 的发生、发病时间、严重程度以及沙利度胺的不良反应。
结果
共纳入 19 例患者。沙利度胺组（2/9，22.2%）的 RCCEP 发生率明显低于卡瑞利珠单抗组（8/10，80%）。RCCEP 的中位发病时间分别为 5 周和 4 周。沙利度胺的不良反应较轻，未观察到与治疗相关的中断。
结论
沙利度胺对接受卡瑞利珠单抗治疗的患者的 RCCEP 显示出良好的预防作用，安全性良好。
相似文献
1
Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.沙利度胺预防卡瑞利珠单抗所致皮肤毛细血管内皮细胞增生症。
Australas J Dermatol. 2022 May;63(2):217-221. doi: 10.1111/ajd.13812. Epub 2022 Mar 1.
2
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
3
Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.沙利度胺单药治疗实现程序性细胞死亡-1抑制剂卡瑞利珠单抗所致反应性皮肤毛细血管内皮细胞增殖完全缓解：一例报告
Exp Ther Med. 2023 May 16;26(1):324. doi: 10.3892/etm.2023.12023. eCollection 2023 Jul.
4
Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.安罗替尼改善了卡瑞利珠单抗诱导的反应性皮肤毛细血管内皮细胞增殖：一例报告
Transl Cancer Res. 2022 Aug;11(8):2940-2945. doi: 10.21037/tcr-22-426.
5
Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.卡瑞利珠单抗单药或联合治疗多种癌症后出现的反应性皮肤毛细血管内皮细胞增生：中国10项研究的大规模汇总分析
Ther Adv Med Oncol. 2024 Apr 10;16:17588359241242607. doi: 10.1177/17588359241242607. eCollection 2024.
6
A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia.沙利度胺治疗卡瑞利珠单抗所致反应性皮肤毛细血管增生症 1 例报告
Medicine (Baltimore). 2023 Jun 30;102(26):e34120. doi: 10.1097/MD.0000000000034120.
7
A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.卡瑞利珠单抗诱导鼻咽癌患者发生反应性皮肤毛细血管内皮细胞增生的病例报告及文献复习
Front Oncol. 2023 Nov 28;13:1280208. doi: 10.3389/fonc.2023.1280208. eCollection 2023.
8
Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.立体定向体部放射治疗（SBRT）诱发肺鳞状细胞癌患者出现反应性皮肤毛细血管内皮细胞增生（RCCEP）的病例回顾。
Exp Hematol Oncol. 2022 Oct 26;11(1):78. doi: 10.1186/s40164-022-00336-4.
9
Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.皮肤毛细血管内皮细胞反应性增殖预测卡瑞利珠单抗治疗复发性/转移性头颈部鳞状细胞癌的疗效。
Med Oral Patol Oral Cir Bucal. 2023 Nov 1;28(6):e525-e529. doi: 10.4317/medoral.25919.
10
Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.卡瑞利珠单抗诱导非小细胞肺癌患者发生反应性皮肤毛细血管内皮增殖的风险：一项回顾性研究
J Thorac Dis. 2023 Dec 30;15(12):6687-6696. doi: 10.21037/jtd-23-1144. Epub 2023 Dec 26.
引用本文的文献
1
Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study.卡瑞利珠单抗在食管癌新辅助化疗中的分析：一项回顾性队列研究。
Oncol Lett. 2025 Jul 17;30(4):449. doi: 10.3892/ol.2025.15195. eCollection 2025 Oct.
2
Efficacy and safety of camrelizumab in combination with S-1 plus oxaliplatin sequenced by camrelizumab-based maintenance therapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study.卡瑞利珠单抗联合S-1及奥沙利铂序贯卡瑞利珠单抗维持治疗作为晚期胃或胃食管交界腺癌一线治疗的疗效及安全性：一项回顾性队列研究
J Gastrointest Oncol. 2025 Apr 30;16(2):342-353. doi: 10.21037/jgo-2025-189. Epub 2025 Apr 27.
3
Management and nursing strategies for different patterns of adverse events in patients with urological cancer treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的泌尿生殖系统癌症患者不同类型不良事件的管理与护理策略
Curr Urol. 2024 Sep;18(3):212-217. doi: 10.1097/CU9.0000000000000223. Epub 2024 Sep 20.
4
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.卡瑞利珠单抗联合阿帕替尼治疗至少一线治疗失败的晚期或复发性子宫内膜癌患者（CAP04）：一项单臂、II 期临床试验。
BMC Med. 2024 Aug 26;22(1):344. doi: 10.1186/s12916-024-03564-z.
5
The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China.帕博利珠单抗治疗复发或转移性头颈部鳞状细胞癌患者的临床结局：一项中国单中心真实世界研究。
Front Oncol. 2024 Feb 19;14:1360657. doi: 10.3389/fonc.2024.1360657. eCollection 2024.
6
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.卡瑞利珠单抗联合阿帕替尼和纳米白蛋白结合型紫杉醇治疗肺腺癌（CAPAP-lung）：一项单臂II期研究。
EClinicalMedicine. 2024 Jan 3;67:102403. doi: 10.1016/j.eclinm.2023.102403. eCollection 2024 Jan.
7
A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.卡瑞利珠单抗联合多西他赛和顺铂用于复发/转移性口腔鳞状细胞癌一线治疗的前瞻性研究。
MedComm (2020). 2023 Jul 22;4(4):e312. doi: 10.1002/mco2.312. eCollection 2023 Aug.
8
Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.沙利度胺单药治疗实现程序性细胞死亡-1抑制剂卡瑞利珠单抗所致反应性皮肤毛细血管内皮细胞增殖完全缓解：一例报告
Exp Ther Med. 2023 May 16;26(1):324. doi: 10.3892/etm.2023.12023. eCollection 2023 Jul.
9
Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation.反应性皮肤毛细血管内皮细胞增生症的新兴治疗方法
Indian J Dermatol. 2023 Jan-Feb;68(1):85-90. doi: 10.4103/ijd.ijd_505_22.
10
Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.预测 TACE 联合卡瑞利珠单抗治疗晚期肝细胞癌的疗效：肿瘤富血管性和反应性皮肤毛细血管内皮细胞增生。
Drug Des Devel Ther. 2022 Sep 30;16:3421-3429. doi: 10.2147/DDDT.S372276. eCollection 2022.
本文引用的文献
1
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.卡瑞利珠单抗联合卡铂和培美曲塞对比单纯化疗用于未经化疗的晚期非鳞状非小细胞肺癌患者（CameL）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18.
2
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.与免疫检查点抑制剂治疗非小细胞肺癌相关的多系统免疫相关不良事件。
JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012.
3
Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities.沙利度胺用于患有严重合并症的患者因血管畸形引起的难治性胃肠道出血。
World J Clin Cases. 2020 Aug 6;8(15):3218-3229. doi: 10.12998/wjcc.v8.i15.3218.
4
Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.恶性淋巴瘤中的免疫检查点抑制剂：进展与展望
Chin J Cancer Res. 2020 Jun;32(3):303-318. doi: 10.21147/j.issn.1000-9604.2020.03.03.
5
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.卡瑞利珠单抗对比研究者选择的化疗作为晚期或转移性食管鳞癌（ESCORT）二线治疗：一项多中心、随机、开放标签、III 期研究。
Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13.
6
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
7
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.免疫检查点抑制剂在胸部恶性肿瘤中的应用：IASLC 专家小组对现有证据的综述及推荐意见
J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14.
8
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.免疫检查点抑制剂免疫相关不良事件的临床特征与治疗
Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb.
9
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.卡瑞利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者的多中心、开放标签、平行分组、随机、Ⅱ期临床试验。
Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.
10
Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer.反应性毛细血管瘤的挽救治疗：阿帕替尼减轻卡瑞利珠单抗在非小细胞肺癌中引起的独特不良事件。
J Cancer Res Ther. 2019;15(7):1624-1628. doi: 10.4103/jcrt.JCRT_997_19.
Zotero 插件